neutral
Recently
Corona Remedies reports strong Q2 growth with profit up over 20%
Corona Remedies posted 15.1% revenue growth and 21.8% profit rise in Q2FY26, supported by stable margins and strong return ratios.
Corona Remedies reported Q2FY26 revenue from operations of ₹361.13 crore, marking a 15.1% year-on-year increase, while net profit rose 21.8% to ₹52.32 crore. For H1FY26, revenue grew 17.0% to ₹707.67 crore and PAT climbed 35.1% to ₹98.52 crore. EBITDA margin stood at 20.9%, with annualised RoE at 31.1%.